Level C· Early human research exploring benefitsProspective StudyPubMed

Quantitative volumetric analysis of progressive hemifacial atrophy corrected using stromal vascular fraction-supplemented autologous fat grafts.

Chang Q., Li J., Dong Z., Liu L., Lu F.

Prospective Study with a reported sample of 10 on Face & Skin, published in Dermatol Surg (2013) — summary generated from the PubMed abstract.

Open my reading list
Level C· Early human research exploring benefitsEvidence level of this study

Early human evidence such as case series or small samples is exploring possible benefits.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Prospective Study
Journal
Dermatol Surg (2013)
Country
United States
Reported sample size
10
Source database
PubMed
PMID
24090256
DOI
10.1111/dsu.12310
Citations
61

Abstract (original English)

Background Progressive hemifacial atrophy (Parry-Romberg disease) is rare and involves all skin layers and subcutaneous soft and hard tissue. Autologous fat grafting has revolutionized the field of soft-tissue reconstruction and augmentation, but long-term maintenance is unpredictable. Stromal vascular fraction (SVF)-supplemented cell therapy offers new hope for improving fat graft survival, with good long-term results, but efficacy and long-term outcome in the clinic are rarely studied using objective data. Objective To compare the long-term viability of SVF-supplemented fat grafts and fat grafts alone for contour reconstruction of progressive hemifacial atrophy using quantitative volume analysis. Methods We treated 20 patients with stable hemifacial atrophy for at least 2 years with SVF-supplemented autologous fat grafting (n = 10) or fat grafting alone (n = 10). All patients were followed up every 3 months. Hemifacial volume was measured using computed tomography and the Philips Extended Brilliance Workspace. Results All patients had successful outcomes without complications, but fat survival and clinical improvement was greater with SVF-supplemented grafting than fat grafting alone after 6 months. Conclusion SVF-supplemented autologous fat transplantation is effective and safe for treating progressive hemifacial atrophy and can enhance the survival of grafts in the face wit

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Early human evidence such as case series or small samples is exploring possible benefits.

How we grade evidence
Adipose TissueAdultFacial HemiatrophyFemaleGraft SurvivalHumansMaleRadiographyStromal CellsTime Factors

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research